Neuroblastoma 1

Common Name(s)

Neuroblastoma 1

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 1" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 1" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Neuroblastoma 1" returned 225 free, full-text research articles on human participants. First 3 results:

Gnetin C, a resveratrol dimer, reduces amyloid-β 1-42 (Aβ42) production and ameliorates Aβ42-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells.
 

Author(s): Syota Seino, Takeru Kimoto, Hidemi Yoshida, Kunikazu Tanji, Tomoh Matsumiya, Ryo Hayakari, Kazuhiko Seya, Shogo Kawaguchi, Kazushi Tsuruga, Hiroshi Tanaka, Tadaatsu Imaizumi

Journal: Biomed. Res.. 2018 ;39(3):105-115.

 

Accumulation and oligomerization of amyloid-beta (Aβ) peptides have been known to be a potent cause of neurodegenerative diseases such as Alzheimer's disease (AD). To expand the possibilities of preventing AD, we investigated the effects of resveratrol dimers, gnetin C and ε-viniferin, ...

Last Updated: 31 Dec 1969

Go To URL
Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth.
 

Author(s): Anna Kock, Karin Larsson, Filip Bergqvist, Nina Eissler, Lotta H M Elfman, Joan Raouf, Marina Korotkova, John Inge Johnsen, Per-Johan Jakobsson, Per Kogner

Journal: EBioMedicine. 2018 Jun;32():84-92.

 

Despite recent progress in diagnosis and treatment, survival for children with high-risk metastatic neuroblastoma is still poor. Prostaglandin E (PGE)-driven inflammation promotes tumor growth, immune suppression, angiogenesis and resistance to established cancer therapies. In neuroblastoma, ...

Last Updated: 31 Dec 1969

Go To URL
Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea.
 

Author(s): Takuma Matsumura, Jiro Terada, Taku Kinoshita, Yoriko Sakurai, Misuzu Yahaba, Kenji Tsushima, Seiichiro Sakao, Kengo Nagashima, Toshinori Ozaki, Yoshio Kobayashi, Takaki Hiwasa, Koichiro Tatsumi

Journal:

 

Although severe obstructive sleep apnea (OSA) is an important risk factor for atherosclerosis-related diseases including coronary artery disease (CAD), there is no reliable biomarker of CAD risks in patients with OSA. This study aimed to test our hypothesis that circulating autoantibodies ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Neuroblastoma 1" returned 1 free, full-text review articles on human participants. First 3 results:

TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy.
 

Author(s): Katharina Batzke, Gabriele Büchel, Wiebke Hansen, Alexander Schramm

Journal:

 

Galectin-1 (Gal-1) has been described to promote tumour growth by inducing angiogenesis and to contribute to the tumour immune escape. We had previously identified up-regulation of Gal-1 in preclinical models of aggressive neuroblastoma (NB), the most common extracranial tumour of ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)
 

Status: Recruiting

Condition Summary: Relapsed or Refractory Neuroblastoma

 

Last Updated: 16 Jul 2018

Go to URL

Last Updated: 14 Nov 2018

Go to URL
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
 

Status: Recruiting

Condition Summary: Neuroblastoma

 

Last Updated: 8 Jun 2018

Go to URL